Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report.
Aged, 80 and over
Anemia, Hemolytic, Autoimmune
/ blood
Anti-Bacterial Agents
/ therapeutic use
Asymptomatic Infections
Azithromycin
/ therapeutic use
C-Reactive Protein
/ immunology
COVID-19
/ blood
Coombs Test
Electrocardiography
Enzyme Inhibitors
/ therapeutic use
Female
Glucocorticoids
/ therapeutic use
Humans
Hydroxychloroquine
/ therapeutic use
Interleukin-6
/ immunology
Platelet Aggregation Inhibitors
/ therapeutic use
Prednisolone
/ therapeutic use
SARS-CoV-2
ST Elevation Myocardial Infarction
/ diagnosis
COVID-19 Drug Treatment
AIHA
Anaemia
COVID-19
Cardiovascular disease
IL-6
Inflammation
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
18 Dec 2020
18 Dec 2020
Historique:
received:
22
08
2020
accepted:
19
11
2020
entrez:
19
12
2020
pubmed:
20
12
2020
medline:
2
1
2021
Statut:
epublish
Résumé
In December 2019, a new coronavirus (named severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) spread from China, causing a pandemic in a very short time. The main clinical presentation of SARS-CoV-2 infection (COVID-19, coronavirus disease-2019) is pneumonia, but several cardiovascular complications may also occur (e.g., acute coronary syndromes, pulmonary embolism, stroke, arrhythmias, heart failure and cardiogenic shock). Direct or indirect mechanisms induced by SARS-CoV-2 could be implicated in the pathogenesis of these events. We report herein the third case of COVID-19 autoimmune haemolytic anaemia (AIHA) reported so far, which occurredwithout any other possible explanations in a Caucasian patient. The patient also suffered from ST-elevation myocardial injury. Both complications occurred quite late after COVID-19 diagnosis and were probably precipitated by systemic inflammation, as indicated by a significant delayed increase in inflammatory markers, including interleukin-6 (IL-6).
Sections du résumé
BACKGROUND
BACKGROUND
In December 2019, a new coronavirus (named severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) spread from China, causing a pandemic in a very short time. The main clinical presentation of SARS-CoV-2 infection (COVID-19, coronavirus disease-2019) is pneumonia, but several cardiovascular complications may also occur (e.g., acute coronary syndromes, pulmonary embolism, stroke, arrhythmias, heart failure and cardiogenic shock). Direct or indirect mechanisms induced by SARS-CoV-2 could be implicated in the pathogenesis of these events.
CASE PRESENTATION
METHODS
We report herein the third case of COVID-19 autoimmune haemolytic anaemia (AIHA) reported so far, which occurredwithout any other possible explanations in a Caucasian patient. The patient also suffered from ST-elevation myocardial injury.
CONCLUSIONS
CONCLUSIONS
Both complications occurred quite late after COVID-19 diagnosis and were probably precipitated by systemic inflammation, as indicated by a significant delayed increase in inflammatory markers, including interleukin-6 (IL-6).
Identifiants
pubmed: 33339534
doi: 10.1186/s13256-020-02595-3
pii: 10.1186/s13256-020-02595-3
pmc: PMC7746982
doi:
Substances chimiques
Anti-Bacterial Agents
0
Enzyme Inhibitors
0
Glucocorticoids
0
Interleukin-6
0
Platelet Aggregation Inhibitors
0
Hydroxychloroquine
4QWG6N8QKH
Azithromycin
83905-01-5
C-Reactive Protein
9007-41-4
Prednisolone
9PHQ9Y1OLM
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
246Investigateurs
Maria Chiara Pelle
(MC)
Bruno Tassone
(B)
Marco Ricchio
(M)
Maria Mazzitelli
(M)
Chiara Davoli
(C)
Giada Procopio
(G)
Anna Cancelliere
(A)
Valentina La Gamba
(V)
Elena Lio
(E)
Giovanni Matera
(G)
Angela Quirino
(A)
Giorgio Settimo Barreca
(GS)
Enrico Maria Trecarichi
(EM)
Carlo Torti
(C)
Eugenio Arrighi
(E)
Bernardo Bertucci
(B)
Maria Teresa Busceti
(MT)
Claudio Carallo
(C)
Francesco Saverio Costanzo
(FS)
Adele De Francesco
(A)
Paolo Fusco
(P)
Luigia Gallo
(L)
Aida Giancotti
(A)
Amerigo Giudice
(A)
Giuseppe Greco
(G)
Domenico Laganà
(D)
Angelo Lamberti
(A)
Maria Carla Liberto
(MC)
Rosaria Lionello
(R)
Nadia Marascio
(N)
Giuseppina Marrazzo
(G)
Maria Petullà
(M)
Graziella Perri
(G)
Vincenzo Scaglione
(V)
Francesca Serapide
(F)
Ciro Indolfi
(C)
Federico Longhini
(F)
Andrea Bruni
(A)
Eugenio Garofalo
(E)
Références
Med Clin (Barc). 2018 Jan 23;150(2):61-63
pubmed: 28743401
Br J Haematol. 2020 Jul;190(1):31-32
pubmed: 32369626
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Mediterr J Hematol Infect Dis. 2020 Jul 01;12(1):e2020054
pubmed: 32670532
Blood. 2010 Sep 16;116(11):1831-8
pubmed: 20548093
Diabetes Metab Syndr. 2020 May - Jun;14(3):247-250
pubmed: 32247212
Curr Opin Immunol. 1996 Dec;8(6):878-85
pubmed: 8994870
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
J Virol. 2000 Jul;74(13):6045-9
pubmed: 10846087
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Am Heart J. 2020 Sep;227:11-18
pubmed: 32425198
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mediterr J Hematol Infect Dis. 2020 Jul 01;12(1):e2020053
pubmed: 32670531
Blood. 2019 Jun 6;133(23):2465-2477
pubmed: 30992265
Br J Haematol. 2020 Jul;190(1):29-31
pubmed: 32374906
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336